review | COPD


It’s doesn’t get more bread and butter than this – the diagnosis and management of stable COPD. Every physician needs to know this through and through, and where better than a freshly updated guidelines. Here’s a brief summary of the updates:


  • Everyone with respiratory symptoms should have spirometry
  • Symptoms + FEV1 of 60-80% = bronchodilators (weak recommendation though)
  • Stable COPD + respiratory symptoms + FEV1 <60% = bronchodilators – use either long acting anti-cholinergics or LABAs (choose based on patient preference, cost, adverse effects)
    • if still symptomatic, consider combination therapies (weak)
  • Pulmonary rehab for those with an FEV1 < 50% (although can be considered for those with higher FEV1s if symptomatic or exercise limited)
  • Oxygen for those with a pO2 <55 or SpO2 <88%

Remember, these guidelines are just an update on the current (from 2007) and are specifically for stable COPD – which is what you mostly see in the clinics. 

Check out the article at the Annals of Internal Medicine, here

IMAGE NIH

review | autoimmune hepatitis


There are so many varieties of hepatitis – the many viruses, drug-related, alcohol, parasites, ischaemia…and of course, autoimmune. After the recent wave of immunosuppressive therapies over the last decade, what’s the deal?




A couple of points from skimming through the article:

  • affects more women that men
  • often has no identifiable precipitant, but sometimes preceded by a virus or new drug
  • presents as persistently abnormal ALT or AST with hyperglobulinaemia
  • 25% asymptomatic at diagnosis, and can be can be acute or chronic in nature
  • diagnosis made with a combination of
    • laboratory
      • high ALT/AST
      • raised serum Ig
        • high IgA makes you think of steatohepatitis
        • high IgM classically associated with PBC
      • negative tests for viral hepatitis
      • high Ab
        • ANA
        • Anti smooth muscle
    • histology
    • clinical features
  • types (check out table 2 in the article
    • 1
      • presence of ANA (homogenous) or anti-smooth muscle
      • anti -SLA/LP is specific, but only present in 10-30% of cases
    • 2
      • anti-LKM1 or anti LC1

Check out the tables with the diagnostic criteria and scoring systems. The article also provides a nice overview of treatment, with an algorithm presented to simplify matters. 

  • treatment usually starts with prednisolone and azathioprine (remember to check TPMT first!)
  • liver biopsy can be used to monitor treatment
  • mycophenolate is an alternative if azathioprine is not tolerated
  • keep transplantation in the back of your mind

It’s a well written article, and most certainly worth the ten minute read – and copy some of those tables and diagrams into your own notes for later. Check it out at Gut, here


SOURCE Gut
IMAGE Reytan

review | endometrial cancer



Of all the gynaecological cancers, this is the one you will be most commonly faced with – so it’s important to know what to look out for, how to work it up, and what needs to be done. For the answers, look to this month’s BMJ. 



The article has a lovely collection of summary points to stimulate your interest, including the hallmark symptom, a brief list of investigations, and treatment options. It’s a fantastic summary and definitely worth a read. 


Over at the BMJ here


IMAGE prep4md

review | tumour lysis syndrome


Breaking down the tumour is usually a good thing – except when there’s a massive load of tumour cells and it all becomes a bit overwhelming. So what exactly happens – and how do you stop it?



Basically, when the cancer cells break down, they release a few nasties – potassium and phosphorus, as well as a few nucleic acids that end up as uric acid. This leads to a multitude of problems, including cardiac arrhythmias, seizures, and renal failure, which all doesn’t help when you’ve just started chemotherapy (although it can happen spontaneously too). 


Look at the bloods, for the following:


– high potassium
– high phosphate
– high uric acid
– high creatinine
– low calcium


The key approaches to management are to prevent the complications, and to choose therapy wisely if someone is at high risk. This article from the New England Journal of Medicine carefully describes the laboratory and clinical diagnosis of tumour lysis syndrome and provides some great algorithms on management.


Read it here


IMAGE euthman

review | primary biliary cirrhosis

File:Primary biliary cirrhosis intermed mag 2.jpg

I’d say there’s a proportion of you out there who’ve heard this term thrown around, hovering around in the back of your mind in regards to causes of cirrhosis, but if it came to actually explaining the pathophysiology and management, things may be a bit more difficult. Good time for a Lancet review then…



In fact, even after flipping through Harrison’s you may not have a complete idea to the processes that lead to this. A couple of important points:

  • it’s an important cause of chronic liver disease
  • often occurs in middle (around 50) aged women
  • it’s characterised by intrahepatic bile duct destruction, leading to cholestasis
  • there’s an autoimmune and genetic component
  • diagnosis is often made with a combination of liver function tests, a positive AMA, and liver biopsy
  • ursodeoxycholic acid slows the progression of disease (the earlier the better)
  • it’s becoming more common – which suggests some form of environmental provoking agent
  • the cure is liver transplantation
Now that you’ve got the brief rundown, why not take some time to check out the seminar over at the Lancet? It’s here

By the way, one of the key features of the above picture is the lymphocytic infiltration around the bile ducts – have a closer look. 

IMAGE Nephron

review | immune thrombocytopaenia


So you get an FBE in a well patient, with platelets that are noted to be 24, and the GP refers to you suspecting ITP. What other bloods do you need to order? What other major disorders do you need to exclude? Do you need to do a bone marrow? What’s the best way to treat?



A diagnosis of exclusion, and yet surprisingly common, ITP is one of those conditions you will definitely deal with at some point. Since 1950, we’ve known about the immune pathogenesis, but it’s still very complex.  Beyond the standard steroid therapy, there are a multitude of other options out there, including IVIg and anti-D, as well as brand new agents like thrombopoietin receptor antagonists (including one with possibly the best drug name ever, eltrombopag). 


The American Society of Haematology has released guidelines for the management in Blood – with a fantastic summary table that gets straight to the point. 


The guidelines are here.

review | multiple myeloma



Surprisingly common in the elderly, but often goes unsuspected – multiple myeloma is a classic haematological malignancy that needs to be well known. What’s more, there have been some significant advances in both diagnosis and treatment that are well deserving of your attention. 

This nice article from NEJM steps you through the management of multiple myeloma, as well as dealing with the adverse effects of treatment. 


Check it out over here


IMAGE: Patrick Hoesly

review | advanced murmurs

File:Austin Flint.jpg



It’s not all just pan systolic this and grade 2 that – murmurs have a lot of subtle nuances, and it’s an area where old school clinical skills come to the fore. We’re not going to deny that echo has revolutionised the diagnosis of valvular heart disease, but picking up a Cabot Locke at the bedside is a damn impressive way to diagnose anaemia.



What is a Cabot Locke murmur I hear you ask? Well that and a collection of other eponymous murmurs are listed for you with a brief review at NEJM, along with some audio for your listening pleasure. 


Check it out here. Oh, and the dude in the picture? Austin Flint. I know – awesome mutton chops.